Drug intelligence / Profile preview

XBB covid-19 vaccine

Development stage: Unknown
Lead developer: Vaxart
Modality: Vaccines & Immunotherapeutics
Administration: Oral

Overview

The XBB covid-19 vaccine is an oral pill vaccine candidate developed by Vaxart. It is designed to induce both systemic and mucosal immunity against the XBB variant of SARS-CoV-2, potentially offering advantages such as easier distribution and administration compared to existing injected vaccines. This vaccine is being developed under the U.S. government's Project NextGen initiative, which aims to develop innovative vaccines with broader and more durable protection.

Beyond the preview

Go deeper on XBB covid-19 vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XBB covid-19 vaccine.

Explore the full profile